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Objectives The purpose of this study was to assess the occurrence, predictors, and mechanisms of optical coherence tomography
(OCT)-detected coronary evaginations following drug-eluting stent (DES) implantation.
Background Angiographic ectasias and aneurysms in stented segments have been associated with a risk of late stent thrombosis. Using
OCT, some stented segments show coronary evaginations reminiscent of ectasias.
Methods Evaginations were defined as outward bulges in the luminal contour between struts. They were considered major eva-
ginations (MEs) when extending≥3 mm along the vessel length, with a depth≥10% of the stent diameter. A total of 228
patientswhohad sirolimus (SES)-, paclitaxel-, biolimus-, everolimus (EES)-, or zotarolimus (ZES)-eluting stents implanted
in 254 lesions, were analysed after 1, 2, or 5 years; and serial assessment using OCT and intravascular ultrasound (IVUS)
was performed post-intervention and after 1 year in 42 patients.
Results Major evaginations occurred frequently at all time points in SES (26%) and were rarely seen in EES (3%) and ZES (2%,
P ¼ 0.003). Sirolimus-eluting stent implantation was the strongest independent predictor of ME [adjusted OR (95% CI)
9.1 (1.1–77.4), P ¼ 0.008]. Malapposed and uncovered struts were more common in lesions with vs. without ME (77 vs.
25%, P, 0.001 and 95 vs. 20%, P, 0.001, respectively) as was thrombus [49 vs. 14%, OR 7.3 (95% CI: 1.7–31.2),
P ¼ 0.007]. Post-intervention intra-stent dissection and protrusion of the vessel wall into the lumen were associated
with an increased risk of evagination at follow-up [OR (95% CI): 2.9 (1.8–4.9), P, 0.001 and 3.3 (1.6–6.9),
P ¼ 0.001, respectively]. In paired IVUS analyses, lesions with ME showed a larger increase in the external elastic
membrane area (20% area change) compared with lesions without ME (5% area change, P, 0.001).
Conclusion Optical coherence tomography-detected MEs are a specific morphological footprint of early-generation SES and are
nearly absent in newer-generation ZES and EES. Evaginations appear to be related to vessel injury at baseline; are asso-
ciated with positive vessel remodelling; and correlate with uncoverage, malapposition, and thrombus at follow-up.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Optical coherence tomography † Intravascular ultrasound † Coronary evaginations † Early-generation drug-eluting
stents † Newer-generation drug-eluting stents † Positive remodelling † Malapposition † Uncovered stent struts
† M.D.R. and L.R. contributed equally to this work.
*Corresponding author. Tel: +31 104635260, Fax: +31 104369154, Email: p.w.j.c.serruys@erasmusmc.nl
Published on behalf of the European Society of Cardiology. All rights reserved.& The Author 2013. For permissions please email: journals.permissions@oup.com
European Heart Journal (2014) 35, 795–807
doi:10.1093/eurheartj/eht344
Introduction
Early-generation drug-eluting stents (DESs) have been associated
with an increased risk of very late stent thrombosis (ST) due to
delayed arterial healing with evidence of prolonged inflammation,
resulting in incomplete endothelialization and acquired malapposi-
tion.1,2 Owing to an ultrahigh resolution (10 mm), optical coherence
tomography (OCT) allows an in vivo histology-like evaluation of
coronary arteries and implanted devices, including the identification
of uncovered and malapposed struts.3,4 Using OCT, it has been
observed that some stented segments show outward vessel
bulging—‘coronary evaginations’—of the luminal contour between
struts during the follow-up.5,6 Three-dimensional (3D) visualization of
these segments suggests an ectatic appearance of the vessel wall rem-
iniscent of that seen in angiographic ectasias and aneurysms, which
were previously shown to be associated with cardiovascular adverse
events.7,8 Although both drugs and polymers of DES have been sus-
pected as culprits for these changes, the specific mechanisms of the
luminal enlargement remain unknown and can only be determined
with serial invasive assessment. At present, there are no data on the
occurrence, predictors, and mechanisms of OCT-detected coronary
evaginations following implantation of early- and newer-generation
DES. The objectives of the present study were therefore to assess
evaginations using OCT at follow-up in a large cohort of patients; and
to investigate the underlying mechanism by serial investigations with
OCT and intravascular ultrasound (IVUS) in a subset of patients.
Methods
Study population
The pooled analysis included OCT acquisitions from the LEADERS-,
RESOLUTE-, and SIRTAX-LATE OCT substudies, and from the Copen-
hagen OCT registry, employing the following stents: Cypher Selectw
(Cordis, Johnson and Johnson, Warren, NJ, USA); Taxus Expressw
(Boston Scientific, Natick, MA, USA); Endeavor Resolutew (Medtronic,
Inc., Santa Rosa, CA, USA); Xience Vw (Abbott Vascular, Santa Clara,
CA, USA); and Biomatrixw (Biosensors, Inc., Newport Beach, CA, USA).
Thedesign andeligibility criteria forLEADERS-, RESOLUTE-, andSIRTAX-
LATE OCT substudies are described in detail elsewhere.6,9,10 The Copen-
hagen OCT registry was a single-centre prospective non-randomized
evaluation of strut coverage and apposition at 12-month follow-up in rela-
tion to apposition at baseline, using the Cypher Selectw, Taxus Expressw,
and Endeavor Resolutew stents. Patients were eligible if they had ≥1
lesion with.50% diameter stenosis in a native coronary artery, with a ref-
erence vessel diameter between 2.25 and 4.0 mm. Exclusion criteria were
ST-segment elevation myocardial infarction (MI), left ventricular ejection
fraction ,30%, renal insufficiency (creatinine .133 mmol/L), and lesion
location in the left main stem or bypass graft. Optical coherence tomog-
raphy and IVUS were performed after a satisfactory angiographic result,
defined as a residual diameter stenosis ,20% and thrombus in MI flow
grade3, and imagingwithbothmodalitieswas repeatedat 1-year follow-up.
A total of 56 consecutive patients were included at baseline out of which
eight withdrew consent for follow-up, and two were excluded due to
system failure or insufficient quality for analysis. Figure 1 shows an overview
of the number of patients, lesions, and stent types included in each cohort,
and the time point of OCT acquisition.
Out of the 46 patients with 48 lesions from the Copenhagen OCT
registry, 43 patients with 45 lesions were available with complete serial
OCT assessment at baseline and follow-up. Out of these, 40 patients
with 42 lesions had a serial IVUS assessment. All studies were conducted
in accordance with the Declaration of Helsinki and approved by the
ethical committees of the involved centres. All patients provided
written informed consent prior to the enrolment.
Optical coherence tomography and
intravascular ultrasound acquisitions
Optical coherence tomography-images were acquired with commercially
available time-domain M2 and M3 systems; and the frequency-domain C7
system from LightLab/St Jude (Westford, MA, USA) at a frame rate of
15.6, 20, and 100 frames/s; and a pullback speed of 1, 3, and 10 mm/s;
with the M2, M3, and C7, respectively. Acquisition with occlusive (M2)
and non-occlusive (M3 and C7) techniques was described previously.11
Intravascular ultrasound images were acquired with the Atlantis SR Pro
40 MHz catheter and iLab system (Boston Scientific, Natick, MA, USA)
at a frame rate of 30 frames/s and pullback speed of 0.5 mm/s, according
Figure 1 Overview of the optical coherence tomography data used for the pooled analysis. FUP, follow-up; SES, sirolimus-eluting stent; PES,
paclitaxel-eluting stent; ZES, zotarolimus-eluting stent; EES, everolimus-eluting stent; BES, biolimus-eluting stent.
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to accepted standards. As for serial investigations, the same imaging
systems were used at baseline and follow-up.
Optical coherence tomography image analysis
The region of interest included the stented segments which were ana-
lysed systematically at 1 mm intervals according to corelab standards
(Cardialysis, BV, Rotterdam, The Netherlands). The methodology is
shown in Figure2A. The lumen- and stent areawere assessed as previously
reported.12 Malapposition was considered to be present when the
distance from the endoluminal strut border to the lumen contour
was larger than the sum of strut metal + polymer thickness, resulting
in cut-offs of ≥160 mm for Cypher, ≥160 mm for Taxus Express, ≥100
mm for Endeavor Resolute, ≥90 mm for Xience V, and ≥130 mm for
the Biomatrix stent.10,12,13 In case of malapposition, the incomplete
Figure 2 Overview of optical coherence tomography image analysis. (A) Frame-level analysis included the assessment of the stent area (blue-
broken trace) and lumen area (white trace). Evaginations were defined as bulges in the luminal contour between struts with a maximum depth
(white double-headed arrow) exceeding the actual strut thickness. Evagination areas were delineated by the stent contour towards the centre
of the lumen and the lumen contour in the opposite direction (broken trace along the luminal contour at 11 o’clock). Struts projecting into the
lumen without separation from the vessel wall were defined as protruding when the distance (yellow double-headed arrow) from the stent area
trace to a ‘lumen help line’ (yellow trace extrapolated between deepest point of evaginations and lumen contour) exceeded the actual strut thick-
ness. (B) A three-dimensional reconstruction of an evagination. Evaginations were considered major when extending ≥3 mm longitudinally, with a
depth≥10% of the stent diameter. Prolapse (C) wasdefined as convex-shaped tissue projecting into the lumen between struts without disruption of
the luminal continuity, and registered only when the distance from the stent area trace (white-dotted line) to the maximum point of prolapse was
≥150 mm. Intra-stent dissections (D) were defined as disruptions of the luminal vessel contour within the stented segment, whereas tissue protru-
sion (E) wasdefined as a mass with an irregular surface attached to the vesselwall or struts and protruding into the lumen. Various features at baseline
(i.e. prolapse, intra-stent dissection, tissue protrusion, and malapposed struts) were cross-correlated with the presence of evaginations in matched
cross-sections at follow-up (F ).
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stent apposition (ISA) area was measured. Struts projecting into the
lumen without obvious separation from the vessel wall were labelled pro-
truding when the distance from the strut marker to a ‘lumen help line’
exceeded that of the actual strut thickness, using the same cut-offs as
for malapposition.5,6 The ‘lumen help line’ was drawn by extrapolating
a trace line between the deepest points in evagination/s and the luminal
vessel contour laterally. Struts within overlapped segments and those
overlying side branch ostia were excluded from the analysis. Struts
were considered uncovered if any part of the strut was visibly exposed
to the lumen, and covered if a layer of tissue was identified above the
struts.3
A coronary evagination (Figure 2A) was defined as the presence of an
outward bulge in the luminal vessel contour between apposed struts
with a maximum depth of the bulge exceeding that of the actual strut
thickness, as measured semi-automatically from the deepest point in
the bulge to the stent area trace using the thickness-ruler function.6
The same cut-offs as for malapposition were used. For each evagin-
ation, we assessed the evagination area defined as the area limited by
the stent contour towards the centre of the lumen and the lumen
contour in the opposite direction. Imaging of evaginations with both
time- and Fourier-domain OCT systems was performed in a few
cases, excluding any influence of OCT system on the appearance of
evaginations.
Evaginations may extend over several consecutive cross-sections, giving
the vessel an ectatic appearance by 3D reconstruction (Figure 2B). Thus,
evaginations can be characterized both at the 2D cross-sectional level,
and along the length of the stented segment. We assessed the presence
ofmajor evagination (ME), defined as the occurrence of cross-sectional eva-
gination in ≥3 adjacent frames (i.e. minimum 3 mm of length) with a
minimal evagination depth of 10% of the nominal stent diameter. Evagin-
ation areas of the various cross-sections belonging to a ME were assumed
to be constant 0.5 mm proximal and distal to the analysed cross-section
in order to calculate evagination volumes for each 1 mm segment. If
evaginations were present in adjacent cross-sections, they were assumed
to be in a continuum, and their volumes were summed up to calculate
the totalevagination volume. In addition,weassessed thepresenceof throm-
bus defined as a mass ≥100 mm in diameter with an irregular surface
attached to the vessel wall or struts and protruding into the lumen.
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Table1 Baseline demographics and baseline patient and lesion level predictors of major evaginations adjusted for time to
follow-up
Characteristics Entire cohort Major evagination at
follow-up
Crude OR (95% CI) P-value Adj OR (95% CI) P-value
n (%) Yes, n (%) No, n (%)
No. of patients 228 31 197
Age 60.0+10.4 59.2+11.0 60.2+10.3 1.00 (0.96–1.04) 1.00 1.00 (0.96–1.05) 0.89
Male gender 179 (78.5) 24 (77.2) 155 (78.7) 0.88 (0.35–2.26) 0.78 0.89 (0.33–2.41) 0.82
Hypertension 127 (55.7) 15 (48.4) 112 (56.9) 0.77 (0.35–1.69) 0.52
Hyperlipidaemia 153 (67.1) 20 (64.5) 133 (67.5) 0.87 (0.38–2.00) 0.74
Diabetes mellitus 44 (19.3) 4 (12.9) 40 (20.3) 0.58 (0.19–1.80) 0.35
Current/previous smoker 87 (38.2) 11 (35.5) 76 (38.6) 0.75 (0.33–1.71) 0.49
Previous MI 58 (25.7) 6 (19.4) 52 (26.7) 0.68 (0.26–1.82) 0.45
LVEF ≤50 42 (18.4) 12 (38.7) 30 (15.2) 3.20 (1.32–7.72) 0.01 2.71 (1.03–7.16) 0.044
STEMI 48 (21.1) 9 (29.0) 39 (19.8) 1.89 (0.74–4.82) 0.19 1.48 (0.49–4.44) 0.48
Stent type 0.0055 0.0084
EES (reference) 27 (11.8) 1 (3.2) 26 (13.2) Reference Reference
PES 55 (24.1) 4 (12.9) 51 (25.9) 2.06 (0.19–22.48) 1.96 (0.17–22.53)
BES 18 (7.9) 2 (6.5) 16 (8.1) 3.26 (0.27–39.38) 3.80 (0.31–46.61)
ZES 37 (16.2) 1 (3.2) 36 (18.3) 0.72 (0.04–12.08) 0.83 (0.05–14.01)
SES 91 (40.0) 23 (74.2) 68 (34.5) 8.84 (1.07–72.97) 9.05 (1.06–77.35)
Multivessel disease 23 (13.4) 3 (10.3) 20 (14.0) 0.61 (0.15–2.57) 0.51
No. of lesions 254 33 221
Target vessel 0.15
Left main (reference) 3 (1.2) 1 (3.1) 2 (0.9) Reference
LAD 101 (40.0) 7 (21.9) 94 (43.1) 0.16 (0.01–2.45) 0.19
Circumflex 57 (22.8) 7 (21.9) 50 (22.9) 0.20 (0.01–3.26) 0.26
RCA 88 (35.2) 17 (53.1) 71 (32.6) 0.47 (0.03–6.93) 0.58
Graft 1 (0.4) 0 (0) 1 (0.5) 0.16 (0.01–2.45) 0.19
Stent diametera 3.0+0.4 3.1+0.4 3.0+0.4 7.05 (0.42–119.3) 0.18
Total stented lengtha 21.6+13.9 22.6+10.4 21.4+14.3 1.00 (0.91–1.11) 0.96
Stents per lesiona 1.4+0.7 1.4+0.8 1.4+0.7 0.91 (0.07–11.12) 0.94
aExpressed as means+ SD.
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The Copenhagen OCT registry included OCT examinations at base-
line and 1-year follow-up. Cross-sections at baseline and follow-up
were matched on the basis of distance from stent borders and the pres-
ence of anatomical landmarks such as side branches. This allowed the fol-
lowing serial assessments at the cross-sectional level (Figure 2C–E):
At baseline, we assessed the presence of tissue prolapse, intra-stent
dissection and tissue protrusion. Tissue prolapse was defined as convex-
shaped tissue with a regular surface protruding into the lumen
between adjacent struts without disruption of the continuity of the
luminal vessel surface.14 The tissue was considered prolapsing only
when thedistance fromthe stent area trace to the maximum point of pro-
lapse was ≥150 mm, chosen arbitrarily since some degree of prolapse
can be seen in most cross-sections. Intra-stent dissections were defined
as disruptions of the luminal vessel contour within the stented
segment, whereas tissue protrusionwas defined as a mass with an irregular
surface attached to the vessel wall or struts and protruding into the
lumen. These features as well as the presence of ≥1 malapposed strut
were then correlated with the presence of evagination at the time of
serial follow-up, in matched cross-sections (Figure 2F).
Intravascular ultrasound image analysis
Intravascular ultrasound pullbacks were analysed off-line using the QCU-
CMS software (Medis, Leiden, The Netherlands) at standard 1 mm inter-
vals, in the same region of interest as for OCT, following the international
consensus.15 Accordingly, we measured the lumen-, stent-, and external
elastic membrane area, the latter referred to as vessel area. The plaque
and media (P&M) area was calculated as (vessel area – stent area –
lumen area outside the stent), and the plaque burden as (P&M area/
vessel area) × 100. Positive vessel remodellingwasdefined as an increase
in the vessel area from baseline to follow-up.
Statistical analysis
We used Bayesian hierarchical random-effects model based on Markov
chain Monte–Carlo simulation methods16 with non-informative priors,
to compare OCT features such as strut malapposition, protrusion, and
coverage between lesions with ME and lesions without. The model
included random-effects at the level of cross-sections and lesions,
accounting for the correlation of characteristics of cross-sections
within lesions, and assigning analytical weights to each lesion depending
on the number of struts or cross-sections observed per lesion. Continu-
ous characteristicsof lesions suchas lumenareaand stent areawerecom-
pared between lesions with vs. without ME using frequentist mixed
maximum-likelihood regression models with study cohort, type of
stent, patient, and/or lesion as random intercepts. Means and standard
deviations were estimated from predicted values. To determine the
association of characteristics of lesions and patients at baseline with the
presence or absence of ME at follow-up, we used mixed maximum logis-
tic regression models adjusted for time to follow-up (1, 2, or 5 years) with
study cohort, type of stent and lesion specified as random intercepts. The
same model was used to analyse stent and lumen area over time as
assessed with OCT and IVUS in the Copenhagen OCT registry. Mixed
maximum logistic regression models with type of stent, patient, and
lesion as random intercepts were used to assess the association of the
baseline cross-sectional OCT features intra-stentdissection, strutmalap-
position, tissue protrusion, and prolapse with cross-sectional evagination
at follow-up, with univariable and multivariable mutual adjustments for all
four features. Statistical analyses were performed using WinBUGS
version 1.4.3 (Imperial College and MRC, UK) and Stata, version 11.0
(StataCorp, College Station, TX, USA).
Results
Incidence and extent of evaginations
A total of 228 patients with 254 lesions containing 5843 frames with
58 967 struts were included in the analysis (Figure 1). Overall, 75.8%
of patients were male and 19.3% had diabetes (Table 1). The clinical
setting at stent implantation was STEMI in 21.1% of cases, and 40.0%
ofpatients receivedaSES.Overall, amedian (IQR)of19(15–26)cross-
sections and 183 (140–273) struts were analysed per lesion. Out of
254 lesions, 152 (59.8%) had at least one cross-section with evagin-
ation, and 33 (13.0%) lesions contained at least one ME. Out of the
33 lesions with ME, 23 had a SES implanted, four a PES, four a BES,
one a ZES, and one an EES. The frequency of cross-sectional and ME
according to stent type and time point of implantation are shown in
Table 2. Both ‘any’ cross-sectional and ME were more frequent in
the SES group when compared with the PES-, ZES-, and EES-groups.
The frequency of ME was low for lesions treated with ZES and EES at
1 year, and PES at 5 years.
Table 3 shows the mean evagination- and ISA volumes per lesion in
lesions with any cross-sectional evagination and lesions with ME
according to stent type and time since implantation. Evagination
volumes were consistently larger for the SES group when compared
with the other stents. Incomplete stent apposition volumes were
similarly larger in SES at 2 and 5 years. Evaluating SES alone, there
was a trend for an increase in ISA volumes from 1 to 2 to 5 years
(all lesions: P ¼ 0.024; lesions with any cross-sectional evagination:
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Table 2 Occurrence of cross-sectional and major evaginations stratified by stent type and time to follow-up
Lesions SES PES BES ZES EES P-value
No. of lesions with any evagination/total no. of lesions (%)
Year 1 22 /31 (71) 4 /8 (50) 25 /43 (58) 13 /35 (37) 0.045
Year 2 16/22 (73) 15 /27 (56) 0.25
Year 5 29 /41 (71) 28/47 (60) 0.37
No. of lesions with major evagination/total no. of lesions (%)
Year 1 8/31 (26) 1 /8 (13) 1 /43 (2) 1 /35 (3) 0.003
Year 2 4/22 (18) 4 /27 (15) 1.00
Year 5 11/41 (27) 3/47 (6) 0.02
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P ¼ 0.016; lesions with ME: P ¼ 0.14). The average depths and
lengths of cross-sectional and ME are presented in the appendix.
Predictors of major evaginations
Table 1 presents patient and lesion characteristics and their associ-
ation with ME. The indication for stent implantation was STEMI in
29.0% of patients with and 19.8% of patients without ME (P ¼
0.19). Left ventricular ejection fraction ≤50% was more frequent in
patients with compared with those without ME, and the use of SES
emerged as an independent predictor for the presence of ME.
Pooled optical coherence tomography
analysis
The quantitative results of the OCT analysis at the time of follow-up
are shown inTable 4. Minimal and average lumen and stent areas were
larger in lesions with when compared with those without ME.
Malapposed, protruding, and uncovered struts were more
common in lesions with than without ME, and found in 77.2 vs.
24.9% (P, 0.001), 97.0 vs. 82.1% (P, 0.001), and 94.6 vs. 20.1%
(P, 0.001) lesions, respectively. Similarly, the proportion of
lesions with≥10% malapposed and uncovered struts was significant-
ly larger in the ME group. The average (means+ SD) thickness of
strut coverage was smaller in lesions with MEs compared with
those without this feature [0.11+0.29 vs. 0.14+ 0.23 mm; differ-
ence (95% CI):20.03 (20.06 to20.004)mm,P ¼ 0.022]. At follow-
up, thrombus was more frequent in lesions with ‘any’ evagination
[28.0 vs. 5.9%, OR (95% CI): 6.1 (2.0–17.1), P ¼ 0.001] as well as
ME [48.5 vs. 14.0%, OR (95% CI): 7.3 (1.7–31.5), P ¼ 0.007].
Serial optical coherence tomography
and intravascular ultrasound analyses
Quantitative serial OCT results are shown in Table 5. All lesions with
ME were implanted with SES. The stent and lumen areas were larger
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Table3 Evagination and incomplete stent apposition volumes at the lesion level in lesion with any and major evaginations
by stent type and time to follow-up
SES PES BES ZES EES P-value
At Year 1
Lesions with any evagination
EV 2.24+1.68 (22) 0.50+0.72 (4) 0.38+1.79 (25) 0.42+1.29 (13) 0.002
ISAV 0.20+2.12 (22) 3.00+0.90 (4) 0.76+2.25 (25) 2.20+1.63 (13) 0.30
Lesions with ME
EV 24.20+1.77 (8) 5.31+0.59 (1) 4.42+0.59 (1) 10.28+0.59 (1) 0.39
ISAV 0.54+1.64 (8) 12.10+0.58 (1) 0.26+0.58 (1) 6.23+0.58 (1) ,0.001
All lesions
ISAV 0.14+1.80 (31) 1.51+0.92 (8) 0.57+2.12 (43) 0.92+1.92 (35) 0.17
At Year 2
Lesions with any evagination
EV 2.47+2.52 (16) 0.57+2.44 (15) 0.03
ISAV 1.54+3.32 (16) 0.19+3.21 (15) 0.24
Lesions with ME
EV 30.40+1.30 (4) 4.08+1.19 (4) 0.01
ISAV 5.22+5.15 (4) 0.79+5.15 (4) 0.21
All lesions
ISAV 1.34+2.69 (22) 0.12+2.98 (27) 0.12
At Year 5
Lesions with any evagination
EV 2.54+1.58 (29) 0.72+1.55 (28) ,0.001
ISAV 3.81+6.69 (29) 1.42+6.57 (28) 0.10
Lesions with ME
EV 11.80+0.59 (11) 4.40+0.25 (3) 0.008
ISAV 7.47+13.52 (11) 1.91+7.06 (3) 0.41
All lesions
ISAV 2.72+5.49 (41) 1.04+5.88 (47) 0.09
ME, major evagination; EV, evagination volume; ISAV, incomplete stent apposition volume. Volumes are expressed as means+ SD (no. of lesions) mm3 and predicted from
maximum-likelihood models.
M. D. Radu et al.800
in lesions with when compared with those without ME at both
baseline and follow-up, with a significant change in the lumen area
at follow-up in both groups [increase in the lumen area in lesions
with ME (P ¼ 0.01), and decrease in the lumen area in lesions
without ME (P, 0.001)]. The change in the stent area from baseline
to follow-up within the ME group was not significant (P ¼ 0.15).
Table 6 shows the association of OCT characteristics recorded at
baseline with cross-sectional evagination at follow-up in matched
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Table 4 Results of follow-up optical coherence tomography analysis
Major evagination at follow-up Difference (95% CI) P-value
Yes No
Lesions analysed, n 33 221
Frames analysed, n 804 5039
Struts analysed, n 8385 50,582
Lumen area, mm2a 8.34+5.90 6.44+2.50 1.90 (1.08–2.72) ,0.001
Minimal lumen area, mm2a 5.99+5.60 4.88+2.20 1.12 (0.34–1.89) 0.005
Stent area, mm2a 8.50+6.10 7.37+3.00 1.13 (0.33–1.93) 0.006
Minimal stent area, mm2a 6.71+6.40 5.88+3.70 0.83 (0.03–1.62) 0.04
Strut type, % (95% CrI)
Malapposed strutsb
Malapposed struts per lesion 1.07 (0.41–2.62) 0.11 (0.06–0.17) 0.96 (0.31–2.52) ,0.001
Lesions with ≥1 77.20 (52.80–92.80) 24.9 (15.40–34.90) 51.80 (25.40–72.60) ,0.001
Lesions with ≥10% 5.53 (0.86–19.30) 0.18 (0.02–1.19) 5.24 (0.70–18.90) 0.001
Protruding strutsb
Protruding struts per lesion 3.04 (1.52–5.87) 0.11 (0.06–0.17) 2.92 (1.42–5.77) ,0.001
Lesions with ≥1 97.00 (86.70–99.60) 82.1 (72.30–89.60) 14.30 (4.04–23.80) 0.01
Lesions with ≥10% 9.34 (2.03–27.10) 4.93 (1.93–10.80) 4.09 (-3.42–21.20) 0.37
Uncovered strutsb
Uncovered struts per lesion 3.82 (2.12–6.82) 1.39 (1.06–1.79) 2.43 (0.70–5.46) 0.002
Lesions with ≥1 94.60 (81.00–99.10) 20.10 (11.40–30.00) 74.00 (56.00–85.80) ,0.001
Lesions with ≥10% 5.59 (0.85–19.30) ,0.01 (,0.01–0.16) 5.57 (0.84–19.30) ,0.001
Lumen and stent areas are expressed as means+ SD.
CrI, credibility interval.
aUsing traditional mixed maximum-likelihood model.
bUsing Bayesian hierarchical 2-level logistic regression model.
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Table 5 Quantitative serial optical coherence tomography results of the stented segment
Major evagination at follow-up Difference (95% CI) P-value
Yes No
Patients analysed, n 8 35
Lesions analysed, n 8 37
Frames analysed, n 154 705
SA BL, mm2 8.60+1.42 7.14+1.22 1.84 (0.32–3.37) 0.02
SA FUP, mm2 9.21+1.59 7.33+1.36 2.28 (0.57–3.98) 0.009
SA change, mm2 0.61+0.29 0.20+0.24 0.43 (-0.02–0.88) 0.06
LA BL, mm2 8.85+1.11 7.30+0.92 1.89 (0.45–3.33) 0.01
LA FUP, mm2 9.03+1.22 6.29+1.01 2.89 (1.27–4.52) ,0.001
LA change, mm2 0.17+0.66 21.00+0.59 0.99 (0.29–1.69) 0.006
Areas are presented as means+ SD.
SA, stent area; LA, lumen area; BL, baseline; FUP, follow-up.
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cross-sections. In both uni- and multivariable analyses, intra-stent dis-
sections, and tissue protrusions at baseline were associated with
cross-sectional evagination at follow-up: the odds of evagination at
follow-up were increased by about three in the presence of either
dissection or tissue protrusion at baseline.
The corresponding serial IVUS analyses are summarized in Table 7.
At baseline, the vessel area was larger among lesions with ME. Serial
IVUS analysis showed a larger increase in the vessel area and positive
remodelling in lesions with ME when compared with those without
(21.1 vs. 4.6%, P, 0.001), mainly driven by an increase in the P&M
area and accompanied by an increase in the lumen area. Again, the
stent area appeared to increase between baseline and follow-up in
lesions with ME (P ¼ 0.84), but not in lesions without [difference in
change between groups (95% CI): 0.43 (0.01–0.85) mm2, P ¼ 0.04].
Discussion
The present study shows that OCT-detected MEs are specifically
related to early-generation SES, and much smaller and in general
less frequent in newer-generation DES. The mechanism underlying
the pathogenesis of ME was suggestively a positive remodelling.
Signs of injury documented immediately after stent implantation
were associated with an increased risk of evagination at follow-up.
Positive remodelling as a cause of coronary
evagination
Coronary artery ectasias and aneurysms following DES implantation
have generated great interest owing to their association with ST.7,8,17
These vessel distensions have often been accompanied by ISA, sug-
gesting positive remodelling as the underlying pathomechanism,
since regional vessel remodelling was previously identified as a cause
of late acquired stent malapposition (LASM).7,17,18 In the present
study, we took advantage of information obtained by OCT on depth,
cross-sectional area, and longitudinal extent, to assess evaginations in
three dimensions. The association between positive remodelling and
ME suggests that positive remodelling is the mechanism underlying
the pathogenesis of evaginations.
We observed that ME in general occurred more frequently and
appeared to be larger in SES, suggesting these to be a specific
morphological footprint of these early-generation DES. Conversely,
MEs were less frequent in PES compared with SES at 5 years—a dif-
ference which is confirmatory of the SIRTAX-LATE OCT study. At 1
year, MEs were less frequent in PES compared with SES but were
almost absent in newer-generation ZES and EES. No difference,
however, was observed between SES and BES at 2 years—something
that needs to be interpreted in light of a relatively low sample size of
only 18 SES and 18 BES patients at 2 years of follow-up. (Accordingly,
it cannot be excluded that this finding could be due to chance. Never-
theless, assessment of evagination volumes showed that these were
significantly larger for SES compared with BES, thus being in line with
the findings in the other subgroups, particularly the SES vs. ZES and
EES, where the sample size was also relatively low.) In a meta-analysis,
Hassan et al.19 reported similar findings in terms of IVUS-detected
LASM, which were also accompanied by positive vessel remodelling,
with the highest incidence in SES followed by PES, and newer-
generationZESand EES.These similarities, together with the observed
association of ME with malapposed, protruding, and uncovered struts,
suggest that these features may be part of the same disease entity.
Pre-clinical and human autopsy studies previously demonstrated
that the inflammatory response following DES implantation strongly
relates to the type of stent: SES typically induces granulomatous
inflammation with macrophages, giant cells, lymphocytes, and eosi-
nophils; PES exhibits extensive fibrin deposition and medial smooth
muscle cell necrosis; ZES and EES show only low levels of inflam-
mation and fibrin deposition.1,20 –22 In addition, SES has been asso-
ciated with marked adventitial inflammation and fibrosis—findings
associated with positive remodelling.20,23 These results are in line
with observations of aneurysmal vessel dilation, stent malapposition,
and generalized eosinophilic vasculitis in a case of late ST in a patient
with SES.24 Similarly, the extent of vascular remodelling predomin-
antly after SES implantation correlated with the number of eosino-
phils harvested from thrombus aspirates in patients with very late
ST,25 supporting the notion that OCT-detected ME represent a
pathological vascular reaction particularly related to this stent.
If evaginations and protruding struts are precursors of ISA, a
stretch in the P&M may occur during the vessel expansion before
complete detachment from the stent. Interestingly, we observed a
trend towards a decrease in the size of ME from 1 and 2 to 5-year
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Crude OR (95% CI) P-value Multivariable OR (95% CI) P-value
Yes No
No. of frames at follow-up 128 713
Characteristics of cross-section at baseline
Intra-stent dissection, n (%) 60 (46.9) 159 (21.8) 3.01 (1.81–5.00) ,0.001 2.93 (1.75–4.89) ,0.001
Malapposed strut, n (%) 12 (9.4) 35 (4.8) 1.76 (0.77–4.03) 0.18 1.69 (0.72–3.99) 0.23
Tissue protrusions, n (%) 27 (21.1) 73 (10.0) 3.27 (1.59–6.70) 0.001 3.34 (1.61–6.93) 0.001
Prolapse, n (%) 26 (20.3) 162 (22.2) 1.04 (0.57–1.90) 0.90 1.06 (0.57–1.99) 0.85
Using mixed logistic regression with stent type, patient, and lesion as random intercept.
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follow-up among SES-stented segments, while there was a trend
towards an increase in ISA volume, suggesting that evaginations
may transition into ISA. Regarding the large ISA volumes at 1 year
in the two cases of PES and ZES with ME; the ISA in the PES repre-
sented persistent malapposition, whereas the ISA in ZES was
located in the proximity of a large bifurcation and thus likely
present at baseline.
The unexpected finding of a larger stent area only in lesions with
ME, which was consistent across the pooled analysis as well as
the serial independent evaluation with OCT and IVUS, may either
be related to the vessel expansion before detachment or due to
chance. It is unlikely that a more intense use of nitroglycerine or po-
tentially higher flush rate during OCT acquisition at follow-up when
compared with baseline could have induced these findings only in
lesions with ME.
Mechanisms of vessel remodelling
The SES-specific remodelling pattern may be triggered by the
polymer rather than the drug. Evidence in favour of this hypothesis
is the presence of a focal giant cell reaction surroundingpolymer rem-
nants separated from the stent struts,24 together with observations
that durable-polymer SES when compared with polymer-free SES
and bare-metal stents are associated with a larger external elastic
membrane area.23 Considering that 80% of sirolimus is released
from durable-polymer SES within the first 4 weeks, it seems unlikely
that sirolimus itself induces long-term alterations of the vessel wall
such as the ME detected up to 5 years in the present study.
The specific mechanisms by which polymers may induce positive
remodelling in cases of coronaryaneurysms and LASM remain specu-
lative. In relation to SES, it is known that methacrylate may exert a
toxic effect on endothelial cells and leucocytes, and can modulate
pro-coagulant activities of monocytes.26 Exposure to the poly-n-
butyl-methacrylate polymer can furthermore cause delayed (type
IV) hypersensitivity reactions mediated at least in part by accumu-
lated CD4 T-helper cells secreting interleukin (IL)-4 and IL-13.24
Of note, IL-13wasassociated with increased smooth muscle cell con-
tractility in asthma,27 andcan inducealveolar remodelling and emphy-
sema in mice via induction of matrix metalloproteinase (MMP)-9 and
MMP-12.28 Both these MMPs were identified as important factors in
the development of abdominal aortic aneurysms in humans by deg-
radation of elastin.29 At the same time, MMP-12 has been found to
be a mediator of the accumulation of macrophages and eosinophils.28
Similar pathways may be responsible for the remodelling and eosino-
philia observed in SES-treated coronary arteries. However, then
remains the question why not all patients develop this finding.
To further address this, we compared OCT findings following
stent implantation with the presence of evaginations at follow-up in
corresponding cross-sections. Accordingly, our study demonstrated
that cross-sections exhibiting intra-stent dissections and tissue pro-
trusions at baseline—both representing markers of injury—were
associated with an increased risk of evagination at the time of OCT
follow-up. (Of note, tissue protrusions were defined as tissue projec-
tions with irregular lumen contour and thereby suggestive of either
thrombus or tissue disruptions other than intra-stent dissections,
whereas tissue prolapses were characterized by an intact lumen
contour, suggestive of prolapsing plaque.) This relationship is sup-
ported by previous observations relating OCT-detected evagina-
tions and coronary artery aneurysms with vessel wall dissections
and deep arterial injury caused by oversized balloons, stents,
and atherectomy.5,30,31 Nevertheless, considering that intra-stent
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Table 7 Quantitative serial intravascular ultrasound results of the stented segment
Major evagination at follow-up Diff (95% CI) P-value
Yes No
SA BL, mm2 8.67+1.94 7.61+1.62 1.31 (20.43 to 3.05) 0.14
SA FUP, mm2 9.18+2.03 7.67+1.68 1.76 (20.09 to 3.60) 0.06
SA change, mm2 0.50+0.31 0.06+0.24 0.43 (0.01 to 0.85) 0.04
LA BL, mm2 8.67+1.92 7.59+1.61 1.33 (20.39 to 3.06) 0.13
LA FUP, mm2 9.28+2.00 7.37+1.63 2.10 (0.24 to 3.97) 0.03
LA change, mm2 0.59+0.40 20.22+0.33 0.75 (0.22 to 1.28) 0.006
VA BL, mm2 16.53+2.63 13.78+1.99 3.44 (0.62 to 6.25) 0.02
VA FUP, mm2 20.06+3.44 14.41+2.76 6.29 (3.00 to 9.59) ,0.001
VA change, mm2 3.51+1.19 0.63+1.00 2.84 (1.71 to 3.98) ,0.001
P&M area BL, mm2 7.86+1.79 6.14+1.56 2.11 (0.52 to 3.70) 0.009
P&M area FUP, mm2 10.78+2.36 7.02+2.06 4.17 (2.08 to 6.27) ,0.001
P&M area change, mm2 2.89+0.92 0.87+0.76 2.06 (1.11 to 3.00) ,0.001
PB BL, % 46.82+4.02 44.36+2.95 3.02 (22.65 to 8.70) 0.30
PB FUP, % 52.78+4.36 48.46+3.15 5.26 (20.93 to 11.46) 0.10
PB change, % 5.90+1.98 3.95+1.72 2.21 (20.08 to 4.49) 0.06
Areas are presented as means+ SD.
SA, stent area; LA, lumen area; VA, vessel area; P&M, plaque and media; PB, plaque burden; BL, baseline; FUP, follow-up.
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dissections were present in 27%, 15%, and 31% of cross-sections in
SES, PES and ZES, respectively, it may be argued that the influence
of stent type, as compared to that of vessel injury, is relatively
greater on the development of ME, which in the serially studied
lesions were all present in segments implanted with SES. Although
the depth of intra-stent dissections could not be systematically
assessed due to the limited tissue penetration of OCT, we did
observe 12 cases of evaginations following intra-stent dissections
extending into the media and adventitia (Figure 3).
Potential clinical relevance of coronary
evaginations
Features associated with very late ST include uncovered struts, late
malapposition, positive remodelling, chronic inflammation as well
as ectasias and aneurysms.1,2,7,8,17,25,32 We found nearly all these fea-
tures to be more common in lesions with ME, suggesting that ME may
be part of the same pathophysiological entity commonly recognized
as inappropriatehealing followingDES implantation, proposing apos-
sible link with late ST. Moreover, our finding of a greater frequency of
thrombus in lesions with ‘any’ and MEs may be an expression of a po-
tential thrombogenicity of these lesions compared with those
without evaginations. Although our pooled study sample included
one of the largest OCT cohorts to date, it was too small for a mean-
ingful evaluation of such a relationship, however, two of the patients
with ME from the SIRTAX-LATE cohort experiencedvery lateSTat5
and 12 months following 5-year OCT follow-up. Both of these oc-
curred in SES which had some of the most extensive evagination-
and ISA volumes in the entire cohort.6 Along the same line,
Alfonso et al.7 described that among patients with angiographic
Figure 3 Co-location of intra-stent dissections post-PCI and evaginations at follow-up. (A–C) Three cross-sections obtained at corresponding
sites before (A1–C1), immediately after (A2–C2), and at 1 year (A3–C3) following stent implantation. The large side-branch (*) in (A1)–(A3) confirms
a good matching, as does the pericardial space (†) and evidence of trilaminar vessel structure (i, intima; m, media; a, adventitia) in (B1)–(B3) and (C1)–
(C3). In (B2) and (C2), a large intra-stent dissection extends from 10 to 1 o’clock (white arrows), exposing the underlying adventitia, and a small dis-
section is seen at 6 o’clock (white arrow). Of note, evaginations (e) are clearly seen at the corresponding sites at follow-up in (B3) and (C3). The upper
middlepanel showsa schematicoverviewof the locationof intra-stentdissectionatbaselineandevaginationat follow-upwithinmatched frames. (D)An
endoscopic three-dimensional view of the vessel in question, where evaginations (e) create an irregular luminal surface. The optical coherence tom-
ography-catheter (Cx) is located to the leftof the ‘pointof view’. (E)Aperpendicular view of theevagination in (B3) and (C3) at 10o’clock (whitee in (E)),
which in the three-dimensional reconstruction is separated from another evagination (black e in (E)) along the vessel segment by a strut (white arrow).
The evagination at 12 o’clock in (C3) is hidden behind the optical coherence tomography-catheter (Cx) in (E).
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coronary artery aneurysms, subsequent ST correlated with a larger
vessel and lumen volume by IVUS at the time of imaging. Similarly,
Imai et al.8 observed an increased risk of ST and target lesion revascu-
larization in SES with ectasias measuring ≥20% of the stent diameter
and extending longitudinally at least the length of the stent diameter,
corresponding to an ectasia depth and length of 0.6 mm and 3 mm in
a 3 mm stent, respectively—a similar length but twice the depth of
the ME definition used in our study. These data suggest that the
extent of evagination matters and that clarification of the natural
history of evaginations as well as the relationship between the
degree of evagination and clinical events merits consideration.
Although first-generation SES are no longer manufactured, they
have been implanted in a considerable number of patients world-
wide. Recent data from a registry of .12 000 patients, and a
meta-analysis including 49 trials, suggest that treatment with newer-
generation EES is associated with a lower risk of very late ST when
compared with early-generation SES and PES,33,34 which are add-
itionally associated with a continued risk of very late ST when com-
pared with EES. In this context, it is interesting that the occurrence
of evaginations, malapposition, and uncoverage by OCT in the
present study, as well as the incidence of IVUS-detected LASM in pre-
vious studies,19 follow a similar pattern. Our findings therefore
suggest that evaginations detected with high-resolution OCT may
be predictors of late ST particularly in SES, and alongside malapposi-
tion and uncoverage provide a possible explanation for differences
in late adverse ischaemic events in early- compared with newer-
generation DES. Conversely, PES when compared with SES
showed fewer ME and only a modest increase when compared
with newer-generation DES. Although clinical rates of ST have
been comparable between SES and PES, the trigger leading to throm-
bosis appears to differ21 in view of substantial differences in the fre-
quency of evaginations. Studies assessing clinical outcomes with
OCT and IVUS—particularly with serial imaging—are demanding
to perform due to the relatively complex and costly set-ups and
the large number of patients required. In view of this, the present
study, although relatively small with the 254 imaged lesions, provides
important new insights into the utility of OCT for assessing vascular
reactions following stent implantation, and suggests that this technol-
ogy can identify features specific for different stents, which may be
useful for improving the prediction of events in the future.
Limitations
The following shortcomings must be considered when interpreting
the results of the present study. First, we pooled data from four sep-
arate cohorts with different time to follow-up, out of which one came
from a non-randomized registry. Efforts were made to adjust for
these issues by using frequentist and Bayesianmixed models account-
ing for the clustered nature of data. Secondly, we did not assess the
type of malapposition at follow-up primarily as our focus was on eva-
ginations, and since the relationship between acquired malapposition
and positive remodelling has already been shown.18 Considering that
positive remodelling is a common denominator of evaginations and
LASM, it seems reasonable to assume that the majority of malap-
posed struts at follow-up within lesions with ME were late acquired,
particularly since there was no correlation between malapposed
struts at baseline and ME at follow-up. Thirdly, we extrapolated
cross-sectional evagination areas 0.5 mm proximal and distal to the
frame of interest to estimate the volume of ME, which may both
over- and underestimate the size. Separate evaluation of cross-
sectional and ME does however not affect the results of the relative
occurrence and predictors of evaginations. Whether this is also
true for the mechanisms is unknown since serial IVUS was only avail-
able for one of the cohorts. In this regard, it cannot be discarded that
evaginations at 2 and 5 years may be caused by mechanisms other
than remodelling as observed at 1 year. Furthermore, OCT cross-
sections were analysed at 1 mm intervals, although the highest sam-
pling density with commercially available new-generation OCT is
0.2 mm. This could potentially give inaccurate estimates of the occur-
rence and size of cross-sectional and ME. Considering that gold-
standard histology typically evaluates entire lesions based on three to
five cross-sections—remarkably lower compared with the average
19 cross-sections per lesion assessed in our study—we chose to
accept this level of accuracy, as well as the potential imprecision in
the selection of corresponding cross-sections at baseline and
follow-up, which is inevitably present whenever serial evaluations are
performed. Also, although care was taken to obtain as accurate mea-
surements of evagination- and ISA-volumes as possible, the inherent
risk of multiplication of small measurement errors cannot be excluded.
Finally, even though this study is one of the largest OCT studies
to date, the small number of lesions with MEs, especially in the
ZES and EES groups at 1 year, nonetheless limits the power of
the study.
Conclusion
Optical coherence tomography-detected MEs are a specific mor-
phological footprint of early-generation SES and are nearly absent
in newer-generation ZES and EES. Optical coherence tomography
detected intra-stent dissections and tissue protrusions at baseline
are associated with an increased risk of evaginations at follow-up.
The mechanism underlying the pathogenesis of ME is suggestively a
positive remodelling.
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Appendix
Addendum to the methodology
and results
Optical coherence tomography and
intravascular ultrasound image analysis
The lumen area (LA) was measured using the automatic area trace
function. Stent struts were defined as signal-intense spots with
dorsal shadowing and a marker was placed at the endoluminal
leading edge of the strut, in the mid-point of its axis. The stent area
(SA) was measured by connecting the strut markers with a trace
line. Strut apposition was assessed for each strut by measuring the dis-
tance fromthe strutmarker to the lumencontour semi-automatically
using the thickness-ruler function.
For the LEADERS and RESOLUTE trials, lumen and stent area
measurements, strut apposition, and strut coverage were assessed
by corelab analysts (Cardialysis) blinded to stent type and clinical out-
comes. The OCT analyses of the SIRTAX-LATE OCT substudy, the
Copenhagen OCT registry, and the assessment of evaginations and
protruding struts in all studies were performed by two observers.
In case of disagreement, a referee was consulted to a final decision.
The time-consuming assessment of evaginations in the LEADERS,
RESOLUTE, and Copenhagen cohorts were performed un-blinded,
as blinding would have implied a detailed assessment of evaginations
using the cut-off of the thinnest stent (Xience, 90 mm or Resolute,
100 mm), and thus the assessment of a large number of bulges in
the thicker stents which would, following un-blinding, not fulfil the
definition of evagination. Assessments of OCT cross-sections at
baseline and follow-up were performed independently, without
knowledge of the characteristics of matched cross-sections. The
same methodology was used throughout all four OCT studies.
Intravascular ultrasound analyses were performed by two obser-
vers, and in case of disagreement a referee was consulted to reach
a final decision. Baseline IVUS assessment was performed independ-
ently of the follow-up evaluation, and without knowledge of the
results of the OCT analysis.
Details of the Bayesian approach
The proportions of malapposed, protruding, and uncovered struts
per lesion were analysed using a model with Bernoulli distribution,
while the proportions of lesions with ≥1 and ≥10% malapposed,
protruding, and uncovered struts were analysed using Bayesian hier-
archical random-effects model with logit distribution. Estimates were
derived fromthemedian of theposterior distribution of the50 001 to
150 000 iteration, with the initial 50 000 iterations discarded as
‘burn-in’. We derived 95% credibility intervals (95% CrI) from the
2.5th and 97.5th percentiles of the posterior distribution, also calcu-
lating two-sidedP-values fromtheposteriordistribution. 95%CrI and
P-values from posterior distributions can be interpreted similarly to
conventional 95% confidence intervals and P-values.
Additional details on the evagination size
The average depths and lengths of cross-sectional and ME are pre-
sented in the appendix table 1 and 2.
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Appendix table 1 Specification of the volume, depth and number of cross-sections spanned for “any” cross-sectional
evaginations, by stent type and time to FUP
SES PES BES ZES EES p
At Year 1
Lesions with any evagination N 22 4 25 13
EV 2.24+1.68 0.50+0.72 0.38+1.79 0.42+1.29 0.002
Max depth 0.36+0.45 0.33+0.19 0.23+0.48 0.25+0.34 0.005
N CS/lesion* 4.02 (2.90–6.68) 2.56 (2.09–3.67) 3.01 (2.34–4.16) 2.26 (1.94–2.88) 0.46
At Year 2
Lesions with any evagination N 16 15
EV 2.47+2.52 0.57+2.44 0.03
Max depth 0.32+0.63 0.26+0.61 0.15
N CS/lesion* 4.41 (3.57–10.96) 2.32 (1.74–8.49) 0.13
At Year 5
Lesions with any evagination N 29 28
EV 2.54+1.58 0.72+1.55 ,0.001
Max depth 0.36+0.80 0.30+0.56 0.13
N CS/lesion* 4.44 (3.99–5.92) 2.25 (1.96–2.73) ,0.001
N CS/lesions refers to the number of CSs per lesion with any evagination. Values are presented as means+ SD unless otherwise specified.
EV, evagination volume; CS, cross-section.
*Expressed as median (IQR). Volumes are expressed in mm3, and depths in mm.
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